MedDataX Logo

COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus

NCT ID: NCT00526279

Last Updated: 2010-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hypertension Atacand/Atacand plus COMBAT Compliance Naturalistic Observational

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who have consented to participation/data release in this study
2. Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision

Exclusion Criteria

1. Secondary hypertension requiring therapy other than antihypertensive medication
2. Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
3. Women in pregnancy or lactation
4. Patients enrolled in any other studies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hyunah Caroline Choi

Role: STUDY_DIRECTOR

AstraZeneca Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Seoul, Jongro-gu, South Korea

Site Status

Research Site

Seoul, Kangnam-gu, South Korea

Site Status

Research Site

Seoul, Songpa-gu, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CKR-ATA-2007/2

Identifier Type: -

Identifier Source: org_study_id